BioSpace News Archive

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET.

Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory Board (“SAB”).

ImpediMed Limited (ASX.IPD), is pleased to announce an abstract comparing concurrent measures using ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference.

CloudCath Inc., a private medical device company advancing real-time fluid analytics and remote monitoring of infectious diseases, announced today it received U.S. Food and Drug Administration (FDA) clearance for the CloudCath System, the world’s first data-driven, cloud-based, remote monitoring platform for PD patients in the $74.5B end-stage renal disease (ESRD) market.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2021 before the market opens on Tuesday, March 1, 2022, and will host a conference call at 8:30 am ET that day to discuss those results.

Trestle Biotherapeutics today announced that it has entered into a license agreement with Kumamoto University.

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors.

Personalis, Inc. today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies.

Aquinnah Pharmaceuticals announced today that it has signed an agreement with Roche to advance the development of brain penetrant oral small molecules to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Ambrx Biopharma Inc. today announced it received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA).